OLFM4 / Olfactomedin-4 Protein (His Tag)

Olfactomedin-4 / OLFM4 Protein

Olfactomedin-4 / OLFM4 Protein Product Information

• Synonym: OLFM4, GC1, GW112, KIAA4294, OLM4, OlfD, UNQ362, bA209J19.1, hGC-1, hOLfD
• Protein Construction: A DNA sequence encoding the human OLFM4 ( NP_006409.3 ) ( Met 1 - Gln 510 ) was fused with a polyhistidine tag at the C-terminus
• Source: Human
• Expression Host: Human Cells

Olfactomedin-4 / OLFM4 Protein QC Testing

• Purity: > 92 % as determined by SDS-PAGE
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.
• Stability: Samples are stable for up to twelve months from date of receipt at -70℃
• Predicted N terminal: Asp 21
• Molecular Mass: The recombinant human OLFM4 consists of 501 amino acids and predictes a molecular mass of 56.6 kDa. In SDS-PAGE under reducing conditions, the apparent molecular mass of rh OLFM4 is approximately 65-70 kDa due to different glycosylation
• Formulation: Lyophilized from sterile PBS, pH 7.4
  1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
  2. Please contact us for any concerns or special requirements.
• SDS-PAGE: OLFM4 protein

Olfactomedin-4 / OLFM4 Protein Usage Guide

• Storage: Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

Olfactomedin-4 / OLFM4 Protein Description

Olfactomedin-4, also known as G-CSF-stimulated clone 1 protein, Antiapoptotic protein GW112, and OLFM4, is a secreted protein which contains one olfactomedin-like domain. OLFM4 is expressed during myeloid lineage development. It is strongly expressed in the prostate, small intestine and colon and moderately expressed in the bone marrow and stomach. OLFM4 is highly expressed in pancreatic cancer tissues and shows an elevated expression level during the early S phase of the cell cycle. It is also expressed at high levels in stomach cancer and colon cancer tissues. Inhibition of ROS or the ERK pathway remarkably decreased G-CSF-induced OLFM4 expression. OLFM4 is an antiapoptotic factor that promotes tumor growth. OLFM4 promotes proliferation of pancreatic cancer cells by favoring the transition from the S to G2/M phase. OLFM4 also facilitates cell adhesion. Induction of OLFM4 in cancer cells was reported to have a novel antiapoptotic action via binding to the potent apoptosis inducer GRIM-19. The human OLFM4 is also thought to be a useful marker for early myeloid development.

References

1. Zhang J., et al., 2002, Gene 283:83-93.
2. Zhang X., et al., 2004, Cancer Res. 64:2474-2481.
3. Kobayashi D., 2007, et al., Cancer Sci. 98:334-340.
4. Kobayashi, D. et al., 2007, Cancer Sci  98 (3): 334-40.
5. van der Flier, L.G. et al., 2009, Gastroenterology. 137 (1):15-7.